Pfizer Inc. $PFE Shares Acquired by Te Ahumairangi Investment Management Ltd

Te Ahumairangi Investment Management Ltd lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 12.7% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 237,946 shares of the biopharmaceutical company’s stock after purchasing an additional 26,834 shares during the period. Te Ahumairangi Investment Management Ltd’s holdings in Pfizer were worth $5,730,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. LM Advisors LLC boosted its position in shares of Pfizer by 3,716.2% in the 2nd quarter. LM Advisors LLC now owns 30,568 shares of the biopharmaceutical company’s stock valued at $739,000 after purchasing an additional 29,767 shares during the period. First Nebraska Trust Co raised its holdings in Pfizer by 1.2% during the 2nd quarter. First Nebraska Trust Co now owns 106,986 shares of the biopharmaceutical company’s stock worth $2,576,000 after buying an additional 1,218 shares during the period. Kendall Capital Management lifted its stake in Pfizer by 9.0% during the second quarter. Kendall Capital Management now owns 49,545 shares of the biopharmaceutical company’s stock valued at $1,193,000 after buying an additional 4,093 shares in the last quarter. Compass Financial Management LLC purchased a new stake in Pfizer during the second quarter valued at about $578,000. Finally, GQG Partners LLC boosted its holdings in shares of Pfizer by 36.4% in the second quarter. GQG Partners LLC now owns 131,567 shares of the biopharmaceutical company’s stock worth $3,168,000 after buying an additional 35,075 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on PFE shares. HSBC downgraded shares of Pfizer from a “buy” rating to a “hold” rating and dropped their target price for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. UBS Group reaffirmed a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Wednesday, May 27th. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research report on Monday, July 6th. Guggenheim cut their target price on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Finally, BMO Capital Markets decreased their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $28.28.

Pfizer Trading Down 0.4%

NYSE PFE opened at $27.97 on Tuesday. Pfizer Inc. has a 1-year low of $23.58 and a 1-year high of $28.75. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $159.41 billion, a PE ratio of 36.80 and a beta of 0.34. The firm’s fifty day simple moving average is $25.34 and its 200-day simple moving average is $26.26.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter last year, the firm earned $0.78 earnings per share. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.1%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is currently 226.32%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.